Our top pick for
Akumin Inc is a diagnostics & research business based in the US. Akumin shares (AKU) are listed on the NASDAQ and all prices are listed in US Dollars. Akumin employs 1,737 staff and has a trailing 12-month revenue of around USD$270.8 million.
|Latest market close||USD$3.5|
|52-week range||USD$2.75 - USD$3.59|
|50-day moving average||USD$3.1626|
|200-day moving average||USD$3.1626|
|Wall St. target price||USD$4.69|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||5.42%|
|1 month (2020-10-23)||-6.42%|
|3 months (2020-08-20)||N/A|
|6 months (2020-05-20)||N/A|
|1 year (2019-11-20)||N/A|
|2 years (2018-11-20)||N/A|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
Valuing Akumin stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akumin's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akumin's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Akumin shares trade at around 70x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Akumin's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$69.5 million.
The EBITDA is a measure of a Akumin's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$270.8 million|
|Operating margin TTM||18.49%|
|Gross profit TTM||USD$142.5 million|
|Return on assets TTM||4.82%|
|Return on equity TTM||4.38%|
|Market capitalisation||USD$244.2 million|
TTM: trailing 12 months
There are currently 10,750 Akumin shares held short by investors – that's known as Akumin's "short interest". This figure is 78% up from 6,038 last month.
There are a few different ways that this level of interest in shorting Akumin shares can be evaluated.
Akumin's "short interest ratio" (SIR) is the quantity of Akumin shares currently shorted divided by the average quantity of Akumin shares traded daily (recently around 59722.222222222). Akumin's SIR currently stands at 0.18. In other words for every 100,000 Akumin shares traded daily on the market, roughly 180 shares are currently held short.
However Akumin's short interest can also be evaluated against the total number of Akumin shares, or, against the total number of tradable Akumin shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akumin's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Akumin shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Akumin shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akumin.
Find out more about how you can short Akumin stock.
We're not expecting Akumin to pay a dividend over the next 12 months.
Over the last 12 months, Akumin's shares have ranged in value from as little as $2.75 up to $3.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akumin's is 1.8964. This would suggest that Akumin's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2019, the company operated 129 imaging centers located in Florida, Pennsylvania, Delaware, Georgia, Texas, Illinois, and Kansas. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.